Hematopoietic Stem Cell Transplant (HSCT)-Associated Microangiopathy (TAM) is a microangiopathic hemolytic anemia seen in a patient following a HSCT. This condition has a high mortality rate, many patients dying within 3 months of diagnosis.
Risk factors:
(1) female gender
(2) transplant from an unrelated donor
(3) presence of graft-vs-host disease (GVHD)
(4) infection with a fungus or virus
(5) therapy with cyclosporine A
(6) therapy with sirolimus
where:
• Therapy with cyclosporine A or sirolimus is related to GVHD.
To read more or access our algorithms and calculators, please log in or register.
